Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VVUS: VIVUS INC. (NASDAQ) -- Ignore unavailable to you. Want to Upgrade?

To: Mkilloran who wrote (11558)	7/16/1998 10:43:00 AM
From: Frostman	Read Replies (2) \| Respond to of 23519

Thursday July 16, 10:14 am Eastern Time Company Press Release VIVUS' MUSE Effective for Many Impotent Men Who Fail or Discontinue Injection Therapy MOUNTAIN VIEW, Calif.--(BW HealthWire)--July 16, 1998--VIVUS, Inc. (NASDAQ:VVUS - news) today announced publication of a recent study in the journal Urology that shows MUSE(R) (alprostadil) is an effective treatment for erectile dysfunction in many men who have failed or discontinued intracavernous injection therapy. The study found that in patients who failed or discontinued prior injection therapy, 58% achieved an erection sufficient for intercourse on at least one of the four doses of MUSE (125 mcg, 250 mcg, 500 mcg, and 1000 mcg) in clinic. Forty-seven percent of these successful patients also reported intercourse during the home treatment phase of the study. As with other studies, most patients required the higher doses of MUSE. The study evaluated the safety and efficacy of MUSE in 452 patients diagnosed with chronic, organic erectile dysfunction who had a prior history of intracavernous injection therapy. A patient questionnaire revealed that 47% rated injection therapy as ''not effective'' or ''sometimes'' effective; the remaining patients rated injection therapy as ''effective.'' All patients had discontinued intracavernous treatment at least 30 days prior to this study and had been unable to achieve an erection sufficient for sexual intercourse without intrarcavernous injection therapy or other treatment for at least three months. ''In the past, men who failed injection therapy were often offered penile implant surgery as their only option. This study demonstrated that MUSE can be an effective option in men who fail to have an adequate response to injection therapy,'' said senior study author Kevin McVary, M.D., Associate Professor of Urology at Northwestern University School of Medicine. ''There are many algorithms for treating erectile dysfunction. These results show that success or failure with one treatment, intracavernosal injections, does not foretell response to another treatment, MUSE. My hope is that these results will open up treatment options for patients who are not adequately treated.'' Founded in 1991, VIVUS, Inc. is a leader in the development of advanced therapeutic systems for the treatment of erectile dysfunction, commonly referred to as impotence. VIVUS has pioneered a novel therapy for erectile dysfunction known as MUSE(R) (alprostadil). This therapy consists of a proprietary, non-invasive drug delivery system that delivers pharmacologic agents via the urethra. MUSE is not for men with sickle cell trait, disease, or other blood disorders. One third of men reported genital pain, causing some to stop use. A few men reported dizziness and, less commonly, fainting. Note to editors: MUSE is a registered trademark of VIVUS, Inc. Additional written materials, recent releases and Company information are available through a variety of sources, including: the VIVUS home page (www.vivus.com) and the VIVUS Fax-On-Demand Service (1-888-329-5719). -------------------------------------------------------------------------------- Contact: